The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered DS102 capsules versus placebo in the treatment of adult patients with Chronic Obstructive Pulmonary Disease (COPD).
Full Title of Study: “A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered DS102 In Chronic Obstructive Pulmonary Disease Patients”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Triple (Participant, Care Provider, Investigator)
- Study Primary Completion Date: January 11, 2019
- Drug: DS102
- Other: Placebo
Arms, Groups and Cohorts
- Placebo Comparator: Placebo
- Participants in this group will receive matching placebo capsules twice daily.
- Experimental: 500mg DS102
- Participants in this group will receive 500 mg DS102 capsules twice daily.
- Experimental: 1000mg DS102
- Participants in this group will receive 1000 mg DS102 capsules twice daily.
Clinical Trial Outcome Measures
- Change in induced sputum differential neutrophil count from baseline to Week 12
- Time Frame: 12 weeks
- Number of Treatment Emergent Adverse Events (TEAEs) in each treatment group leading to treatment discontinuation.
- Time Frame: 12 Weeks
- Change in induced sputum neutrophil differential count from baseline
- Time Frame: 14 weeks
- Change in St Georges Respiratory Questionnaire (SGRQ) from baseline
- Time Frame: 14 weeks
- Questionnaire designed to measure impact of COPD on overall health, daily life and perceived well-being. Scores range from 0 -100 with higher scores indicating more limitations.
Participating in This Clinical Trial
- Patients (male or female) aged 40-75 years with stable COPD at the time of screening. – Patients who are current or ex-smokers who have a smoking history of at least 10 pack years (Ten pack- years are defined as 20 cigarettes a Day for 10 years, or 10 cigarettes a Day for 20 years). – Patients whose pre-study clinical laboratory findings do not interfere with their participation in the study, in the opinion of the Investigator. – Patients who are able to communicate well with the Investigator, to understand and comply with the requirements of the study, and understand and sign the written informed consent. Exclusion Criteria:
- Patients with a history of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin. – Patients with significant systemic or major illness other than pulmonary disease, including coronary artery disease, liver disease, cerebrovascular disease, renal insufficiency, serious psychiatric disease, respiratory or hypertensive disease, as well as diabetes and arthritis that, in the opinion of the Investigator, would preclude the patient from participating in and completing the study. – Patients with known hypersensitivity to any ingredients of the study treatment. – Patients, in the opinion of the Investigator, not suitable to participate in the study
Gender Eligibility: All
Minimum Age: 40 Years
Maximum Age: 75 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Provider of Information About this Clinical Study
- Overall Official(s)
- Ian Pavord, MA DM FRCP FERS FMedSci, Principal Investigator, University of Oxford, Oxford, UK
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.